The impact of durvalumab for resectable non-small cell lung cancer

AEGEAN Study - FDA Approval of Durvalumab in Resectable Non-Small Cell Lung CancerПодробнее

Impact of Durvalumab as Consolidation Therapy in NSCLCПодробнее

Stage III NSCLC: When to Start DurvalumabПодробнее

[lung]The role of durvalumab in patients with stage 3 lung cancer in a real hospitalПодробнее

Durvalumab Tolerability in Non–Small Cell Lung CancerПодробнее

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLCПодробнее

Trials in EGFR Mutated NSCLC: Flaura2 and Mariposa- 2024 Leading Developments in Lung CancerПодробнее

Dr. Simon on Durvalumab for Patients With Lung CancerПодробнее

Advances in Immunotherapy & Resectable Non-Small Cell Lung CancerПодробнее

FDA Approves Durvalumab / Imfinzi for Resectable NSCLC Non-Small Cell Lung CancerПодробнее

Impact of radiation dose to immune cells in unresectable or stage III NSCLC in the durvalumab eraПодробнее

The Use of Durvalumab in Locally Advanced NSCLCПодробнее

How Breakthroughs in Immunotherapy are Helping Non-Small Cell Lung Cancer Patients Live LongerПодробнее

Perioperative Chemoimmunotherapy in Lung Cancer | NEJMПодробнее

Implications for Using Durvalumab in Stage 3 NSCLCПодробнее

Phase II study of Durvalumab for patients with NSCLCПодробнее

Durvalumab improves PFS in stage III lung cancerПодробнее

PACIFIC 6: durvalumab after sCRT in patients with NSCLCПодробнее

Dr. Feldman on Durvalumab for Patients With Lung CancerПодробнее

Dr. Langer on the Benefit of Durvalumab in Stage III NSCLCПодробнее